Jongen-Lavrencic et al. recently demonstrated no adverse effect of persisting DNMT3A, TET2 and ASXL1 mutations in the absence of other genetic alterations in a cohort of 482 AML patients achieving first remission after two cycles of intensive induction treatment, thereby allocating them to CHIP rather than to a pre-relapse condition. The gene discussed is ASXL1; the disease is acute myeloid leukemia.